STJ : Summary for St. Jude Medical, Inc. - Yahoo Finance

U.S. Markets closed

St. Jude Medical, Inc. (STJ)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
80.820.00 (0.00%)
At close: 4:01PM EST
People also watch
BSXSYKMDTVARBCR
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close80.82
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume2,671,780
Market Cap23.09B
BetaN/A
PE Ratio (TTM)35.14
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga14 days ago

    Dept. of Homeland Security Provides A Timely Update On Abbott, St. Jude

    Abbott Laboratories (NYSE: ABT )'s acquisition of St. Jude Medical Inc (previously traded (NYSE: STJ ) doesn't erase an ongoing concerns shared by many investor, which were brought into the spotlight by ...

  • Barrons.com19 days ago

    No "Sophomore Slump" Ahead For Boston Scientific

    Shares of Boston Scientific (BSX) shot more than 4% higher today after the medical device maker unveiled fourth quarter financial results that beat expectations. “Boston Scientific ended 2016 on a very good note, and enters 2017 with a promising product pipeline and lots of momentum to avoid a sophomore slump,” writes Joanne Wuensch, an analyst at BMO Capital Markets. The company says it will earn between $1.22 a share and $1.26 a share compared to consensus of $1.25 a share.

  • Barrons.com19 days ago

    Edwards Lifesciences Sinks 9%; Is This A Buying Opportunity?

    Edwards Lifesciences (EW) unveiled fourth quarter financial results last night that beat expectations thanks to accelerating demand for its minimally-invasive artificial heart valve. At BTIG, analyst Sean Lavin cut Edwards Lifesciences to a neutral with a $110 price target, citing worries that growth in U.S. sales of the transcatheter heart valves will “get tougher.” Meanwhile, Leerink’s Danielle Antalffy argued that Edwards will have a hard time beating consensus expectations over the next 12 to 18 months amid rising competition. As Antalffy writes: Edwards is the current market leader in the $5B+ TAVR (transcatheter aortic valve replacement) market, both in the U.S. and OUS.